Skip to main content Accessibility help
  • Print publication year: 2007
  • Online publication date: September 2010

12 - Patterns of recurrence following therapy for rectal cancer

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Colorectal Cancer
  • Online ISBN: 9780511902468
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to *
Heald, R. J., Husband, E. M., and Ryall, R. D.The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?Br J Surg, 69:10 (1982), 613–16.
Quirke, P. and Dixon, M. F.The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorectal Dis, 3:2 (1988), 127–31.
Heald, R. J. and Ryall, R. D.Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, 1:8496 (1986), 1479–82.
Nesbakken, A., Nygaard, K., Westerheim, O., Mala, T., and Lunde, O. C.Local recurrence after mesorectal excision for rectal cancer. Eur J Surg Oncol, 28:2 (2002), 126–34.
Havenga, K., Enker, W. E., Norstein, J., et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol, 25:4 (1999), 368–74.
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med, 336:14 (1997), 980–7.
Folkesson, J., Birgisson, H., Pahlman, L., et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol, 23:24 (2005), 5644–50.
MacFarlane, J. K., Ryall, R. D., and Heald, R. J.Mesorectal excision for rectal cancer. Lancet, 341:8843 (1993), 457–60.
Enker, W. E., Thaler, H. T., Cranor, M. L., and Polyak, T.Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg, 181:4 (1995), 335–46.
Aitken, R. J.Mesorectal excision for rectal cancer. Br J Surg, 83:2 (1996), 214–16.
Heald, R. J., Moran, B. J., Ryall, R. D., Sexton, R., and MacFarlane, J. K.Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg, 133:8 (1998), 894–9.
Arbman, G., Nilsson, E., Hallbook, O., and Sjodahl, R.Local recurrence following total mesorectal excision for rectal cancer. Br J Surg, 83:3 (1996), 375–9.
Kapiteijn, E., Marijnen, C. A., Nagtegaal, I. D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345:9 (2001), 638–46.
Houbiers, J. G., Brand, A., Watering, L. M., et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet, 344:8922 (1994), 573–8.
Kapiteijn, E., Putter, H., and Velde, C. J.Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg, 89:9 (2002), 1142–9.
Marijnen, C., Peeters, K., Putter, H., et al. Long term results, toxicity and quality of life in the TME trial. Proc Am Soc Clin Oncol, 23: 16 Suppl. (2005).
Gunderson, L. L., Sargent, D. J., Tepper, J. E., et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol, 22:10 (2004), 1785–96.
Nagtegaal, I. D., Marijnen, C. A., Kranenbarg, E. K., van de Velde, C. J., and van Krieken, J. H.Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol, 26:3 (2002), 350–7.
Wibe, A., Rendedal, P. R., Svensson, E., et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg, 89:3 (2002), 327–34.
Marr, R., Birbeck, K., Garvican, J., et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg, 242:1 (2005), 74–82.
Tominaga, T., Sakabe, T., Koyama, Y., et al. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer, 78:3 (1996), 403–8.
Carlsson, U., Lasson, A., and Ekelund, G.Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis Colon Rectum, 30:6 (1987), 431–4.
Rao, A. R., Kagan, A. R., Chan, P. M., et al. Patterns of recurrence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer, 48:6 (1981), 1492–5.
Mendenhall, W. M., Million, R. R., and Pfaff, W. W.Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys, 9:7 (1983), 977–85.
Cass, A. W., Million, R. R., and Pfaff, W. W.Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer, 37:6 (1976), 2861–5.
Pilipshen, S. J., Heilweil, M., Quan, S. H., Sternberg, S. S., and Enker, W. E.Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer, 53:6 (1984), 1354–62.
Hruby, G., Barton, M., Miles, S., et al. Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. Int J Radiat Oncol Biol Phys, 55:1 (2003), 138–43.
Chau, I., Norman, A. R., Cunningham, D., et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16:4 (2005), 549–57.
Starling, N., Brown, G., Tait, D., Norman, A., and Cunningham, D.Patterns of pelvic recurrence in patients with rectal cancers treated with adjuvant chemotherapy in a multicentre randomised study. Proc Am Soc Clin Oncol, 23:16 suppl. (2005).
Larsen, S. G., Wiig, J. N., and Giercksky, K. E.Hydronephrosis as a prognostic factor in pelvic recurrence from rectal and colon carcinomas. Am J Surg, 190:1 (2005), 55–60.
Cheng, C., Rodriguez-Bigas, M. A., and Petrelli, N.Is there a role for curative surgery for pelvic recurrence from rectal carcinoma in the presence of hydronephrosis?Am J Surg, 182:3 (2001), 274–7.
Ulm, A. H. and Klein, E.Management of ureteral obstruction produced by recurrent cancer of the rectosigmoid colon. Surg Gynecol Obstet, 110 (1960), 413–18.
Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med, 312:23 (1985), 1465–72.
Krook, J. E., Moertel, C. G., Gunderson, L. L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 324:11 (1991), 709–15.
Douglass, H. O. Jr., Moertel, C. G., Mayer, R. J., et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med, 315:20 (1986), 1294–5.
Gray, R. G., Barnwell, J., Hills, R., et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol, 22:14 suppl. (2004).
Fisher, B., Wolmark, N., Rockette, H., et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst, 80:1 (1988), 21–9.
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet, 358:9290 (2001), 1291–304.
Cedermark, B., Johansson, H., Rutqvist, L. E., and Wilking, N.The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm colorectal cancer study group. Cancer, 75:9 (1995), 2269–75.
Martling, A., Holm, T., Johansson, H., Rutqvist, L. E., and Cedermark, B.The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer, 92:4 (2001), 896–902.
Camma, C., Giunta, M., Fiorica, F., et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA, 284:8 (2000), 1008–15.
Sauer, R., Becker, H., Hohenberger, W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351:17 (2004), 1731–40.
Bosset, J. F., Calais, G., Mineur, L., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results – EORTC 22921. J Clin Oncol, 23:24 (2005), 5620–7.
Bosset, J. F., Calais, G., Mineur, L., et al. Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. Proc Am Soc Clin Oncol, 23:16 suppl. (2005).
Gerard, J., Bonnetain, F., Conroy, T., et al. Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3–4 rectal cancers: results of the FFCD 9203 randomized trial. Proc Am Soc Clin Oncol, 23:16 suppl. (2005).
Phillips, R. K., Hittinger, R., Blesovsky, L., Fry, J. S., and Fielding, L. P.Local recurrence following ‘curative’ surgery for large bowel cancer: I. The overall picture. Br J Surg, 71:1 (1984), 12–16.
Moore, E., Heald, R. J., Cecil, T. D., et al. Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences. Colorectal Dis, 7:4 (2005), 403–5.
Tepper, J. E., O'Connell, M., Hollis, D., et al. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from intergroup study 0114. J Clin Oncol, 21:19 (2003), 3623–8.
Desch, C. E., Benson, A. B. III, Somerfield, M. R., et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol, 23:33 (2005), 8512–19.
Figueredo, A., Rumble, R. B., Maroun, J., et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer, 3: (2003), 26.
Renehan, A. G., Egger, M., Saunders, M. P., and O'Dwyer, S. T.Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ, 324:7341 (2002), 813.
Jeffery, G. M., Hickey, B. E., and Hider, P.Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev, 1 (2002), CD002200.
Pietra, N., Sarli, L., Costi, R., et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum, 41:9 (1998), 1127–33.
Chau, I., Allen, M. J., Cunningham, D., et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol, 22:8 (2004), 1420–9.
Saini, A., Norman, A. R., Cunningham, D., et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer, 88:12 (2003), 1859–65.
Tepper, J. E., O'Connell, M. J., Petroni, G. R., et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol, 15:5 (1997), 2030–9.
Tepper, J. E., O'Connell, M., Niedzwiecki, D., et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114. J Clin Oncol, 20:7 (2002), 1744–50.
Tveit, K. M. and Kataja, V. V.ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of rectal cancer. Ann Oncol, 1: suppl. 16 (2005), i20–1.